Drug Development Pharmacokinetics Small Molecule 
Drug Discovery World
AUGUST 14, 2023
Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Targeting EP4 to block the effects of PGE2 increases the ability of the immune system to detect and control cancer cells.
The Premier Consulting Blog
AUGUST 8, 2024
Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch. For example, pharmacokinetic (PK) data from a comparative BA study and PK modeling approaches (e.g.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 26, 2022
In terms of the benefits drug repurposing can bring, Jackson says that if “done right, a drug developer has an opportunity to reduce overall drug development risk through some of these repurposing strategies.” . “In The post Highs and lows of drug repurposing appeared first on Drug Discovery World (DDW).
Metabolite Tales Blog
APRIL 10, 2024
Where data was publicly available, the routes of human metabolism for each of the drugs in this subset is listed in Table 1. It is proposed that the decreased clearance of the drug observed in patients may be due to depletion of GSH in this population [10]. Clin Pharmacokinet. 2023; 62(12):1765-1779.
Alta Sciences
JANUARY 31, 2024
Pharmacokinetics, Pharmacodynamics and Toxicokinetics Demystified pmjackson Wed, 01/31/2024 - 14:55 Understanding the effects of a drug, and how it interacts with the body, and vice versa, is critical to ensure it is safe for human use. This is where pharmacokinetic (PK), pharmacodynamic (PD) , and toxicokinetic (TK) analyses step in.
Drug Discovery World
APRIL 12, 2023
This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
Drug Discovery World
JANUARY 20, 2023
This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
Expert insights. Personalized for you.
130 
Let's personalize your content